NCT01438606View on ClinicalTrials.gov

Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2013

Conditions
HIV Infections
Interventions
BIOLOGICAL

VSV-Indiana HIV gag vaccine

Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.

BIOLOGICAL

Placebo injection (normal saline)

Administered IM in both deltoids at baseline and Week 8.

Trial Locations (4)

19104

Penn Prevention CRS, Philadelphia

30030

The Hope Clinic of the Emory Vaccine Center CRS, Decatur

37232

Vanderbilt Vaccine (VV) CRS, Nashville

94143

Bridge HIV CRS, San Francisco

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01438606 - Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults | Biotech Hunter | Biotech Hunter